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ABSTRACT
Two compounds known to covalently bind to DNA after their activation with cytochromes P450 (CYPs), carcinogenic benzo(a)pyrene 
(BaP) and an antineoplastic agent ellipticine, were investigated for their potential to induce CYP and NADPH:CYP reductase (POR) 
enzymes in rodent livers, the main target organ for DNA adduct formation. Two animal models were used in the study: (i) rats as 
animals mimicking the fate of ellipticine in humans and (ii) mice, especially wild-type (WT) and hepatic POR null (HRN™) mouse lines. 
Ellipticine and BaP induce expression of CYP1A enzymes in livers of experimental models, which leads to increase in their enzymatic 
activity. In addition, both compounds are capable of generating DNA adducts, predominantly in livers of studied organisms. As 
determined by 32P postlabelling analysis, levels of ellipticine-derived DNA adducts formed in vivo in the livers of HRN™ mice were 
reduced (by up to 65%) relative to levels in WT mice, indicating that POR mediated CYP enzyme activity is important for the activation 
of ellipticine. In contrast to these results, 6.4 fold higher DNA binding of BaP was observed in the livers of HRN™ mice than in WT mice. 
This finding suggests a detoxication role of CYP1A in BaP metabolism in vivo. In in vitro experiments, DNA adduct formation in calf 
thymus DNA was up to 25 fold higher in incubations of ellipticine or BaP with microsomes from pretreated animals than with controls. 
This stimulation effect was attributed to induction of CYP1A1/2 enzymes, which are responsible for oxidative activation of both 
compounds to the metabolites generating major DNA adducts in vitro. Taken together, these results demonstrate that by inducing 
CYP1A1/2, ellipticine and BaP modulate their own enzymatic metabolic activation and detoxication, thereby modulating their either 
pharmacological (ellipticine) and/or genotoxic potential (both compounds). 
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A CoMPARATIVe STUdy
Introduction
Ellipticine  and  benzo[a]pyrene  (BaP)  are  compounds 
exhibiting significant biological activities. Ellipticine is an 
efficient anticancer agent (for a summary, see Stiborová et 
al., 2006b), while BaP is a strong carcinogen (for a summary, 
see Arlt et al., 2008). Therefore, both two compounds were 
employed by us for studies concerning their phatmacologi‑
cal and toxicological effects.
Ellipticine,  an  alkaloid  isolated  from  Apocyanaceae 
plants, and its derivatives exhibits significant antitumor 
and anti‑HIV activities, characterized by high efficiencies 
against several types of cancer and rather limited toxic side 
effects, including complete lack of hematological toxicity. 
Nevertheless,  ellipticines  are  potent  mutagens.  Several 
mechanisms of their antitumor, mutagenic and cytotoxic 
activities have been hitherto suggested: (i) intercalation 
into DNA; (ii) inhibition of DNA topoisomerase II activity; 
(iii) selective inhibition of p53 protein phosphorylation; 
(iv) disruption of the energy balance of cells by uncoupling 
mitochondrial oxidative phosphorylation (for a summary, 
see Stiborová et al., 2001; 2006b). Recently, we have shown 
that ellipticine also binds covalently to DNA in vitro and in 
vivo, after being enzymatically activated with cytochromes 161
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P450 (CYP) (Figure 1) or peroxidases, suggesting a third pos‑
sible mechanism of action (Stiborová et al., 2001; 2003a,b; 
2004; 2007a).
On the basis of in vitro studies, human and rat CYPs 
of 1A and 3A subfamilies seem to be the predominant 
enzymes oxidizing ellipticine either to metabolites that are 
excreted (7‑ or 9‑hydroxyellipticine) or form DNA adducts 
(12‑ or 13‑hydroxy‑ellipticine) (Stiborová et al., 2001; 2003b; 
2004; 2006; Kotrbová et al., 2006). Besides these CYPs, 
peroxidases such as mammalian cyclooxygenases (COX‑1 
and ‑2), lactoperoxidase and myeloperoxidase, efficiently 
generate the same ellipticine‑derived DNA adducts in vitro 
(Stiborová et al., 2007a; Poljaková et al., 2006). Identical 
DNA adducts were also detected in cells in culture, in which 
both CYPs and peroxidases are expressed, such as human 
breast adenocarcinoma MCF‑7 cells (Bořek‑Dohalská et al., 
2004), leukemia HL‑60 and CCRF‑CEM cells (Poljaková et 
al., 2007) and V79 Chinese hamster lung fibroblasts trans‑
fected with human CYP3A4, 1A1 and 1A2 (Frei et al., 2002). 
After i.p. administration of ellipticine, the ellipticine‑DNA 
adduct levels seem to be related to CYP3A1 and 1A content 
in different tissues of rat, but the real impact of CYPs or 
peroxidases in this process could not be still exactly evalu‑
ated (Stiborová et al., 2003a, 2007b). 
BaP, as the second model compound in this comparative 
study is, similarly to the other polycyclic aromatic hydro‑
carbons (PAHs), mutagenic and carcinogenic (IARC, 1983; 
Phillips 1999, 2002). PAHs are produced mainly by incom‑
plete combustion or pyrolysis of organic matter and are 
ubiquitous in the environment, leading to measurable back‑
ground levels of exposure in the general population (IARC, 
1983). Beside the inhalation of polluted air, the main routes 
of exposure are through tobacco smoke, diet (Phillips 1999, 
2002) and occupational exposition throughout e.g. coal, coke 
or coal‑tar processing and use of coal‑tar products (IARC, 
1983). Prior to the reaction with DNA, BaP analogously to 
ellipticine requires metabolic activation (Figure 2), which is 
an essential step in the mechanism by which BaP exerts its 
genotoxic effects. CYP1A1 and CYP1B1 are widely accepted 
to be the most important enzymes in the metabolic activa‑
tion of BaP (Baird et al., 2005). However, current studies 
show that BaP‑induced DNA damage was increased in mice 
lacking CYP1A1, indicating that in vivo the CYP1A1 enzyme 
plays a detoxification role, and protects mice against BaP 
toxicity (Uno et al., 2004, 2006). PAHs affect the expression 
of numerous enzymes involved in metabolism of xenobiotics 
(including CYP1A1) mainly via the aromatic hydrocarbon 
receptor (AhR). AhR‑dependent inducibility was correlated 
to the predisposion to some types of cancer (Kouri et al., 
1973).
The detailed knowledge on the role of CYP enzymes in 
activation and/or detoxication of BaP and ellipticine and that 
on their induction mediated by these xenobiotics, is crucial 
for the possibility to modify their carcinogenic and/or the 
therapeutic efficiency. Therefore, this field was extensively 
investigated in our laboratory. To investigate the real role 
of CYPs in metabolism of both compounds, we have used 
several animal models, such as rats, rabbits and/or mice in 
our previous studies (Stiborová et al., 2001; 2003a; b; 2004; 
2006; 2007b; 2008; Kotrbová et al., 2006; Arlt et al., 2008). 
In the case of mice, the HRN™ (Hepatic Cytochrome P450 
Reductase Null) mice, the mouse line lacking the hepatic 
NADPH:CYP oxidoreductase (POR), the unique electron 
donor to CYPs, which results in the loss of essentially all 
hepatic CYP function (Henderson et al., 2003, 2006), was 
utilized (Stiborová et al., 2008; Arlt et al., 2008). 
 
Figure 1. Metabolism and activation of ellipticine (5,11-dimethyl-6H-pyrido[4,3-b]carbazole) by cytochromes P450.162
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Here, we summarize the results obtained with rats and 
mice previously, and present novel data obtained with these 
animal models. Such a study is necessary to evaluate results 
found till the present time and to suggest which further 
studies are necessary to improve our knowledge in this field.
Material and Methods
Animal models 
The  study  was  conducted  in  accordance  with  the 
Regulations for the Care and Use of Laboratory Animals 
(311/1997, Ministry of Agriculture, Czech Republic), which 
complies with Declaration of Helsinki. Rats, the animal 
model found to be suitable to mimic the fate of ellipticine in 
humans (Stiborová et al., 2003a; 2006), and two mouse lines, 
namely,.(i) „Hepatic Reductase Null“ (HRN™ ) mice based on 
a C57BL/6 background (CXR Bioscience Ltd, Dundee, UK), 
in which NADPH:cytochrome P450 reductase (POR) is spe‑
cifically deleted in the liver (Porlox/lox + CreALB) (Henderson 
et al., 2003, 2006) and (ii) mice homozygous for loxP sites at 
the Por locus (Porlox/lox) as wild‑type (WT) mice, were used 
in this study.
Treatment of animals with ellipticine and benzo(a)pyrene
Male and female Wistar rats (~100 g) were treated with a 
single dose of 4, 40 or 80 mg/kg body weight (n = 3) of ellipti‑
cine by intraperitoneal injection as described (Aimová et al., 
2007). Ellipticine was dissolved in sunflower oil/dimethyl 
sulphoxide (1:1, v/v) at a concentration of 6 mg/ml, control 
animals (n = 3) received solvent only. The doses of ellipticine 
used for the treatment of rats are in the range of dosage in 
human therapy (80–100 mg/m2). 
Groups (n = 3) of female HRN™ and WT mice (3 months 
old, 25–30 g) were treated intraperitoneally with a single 
dose of 10 mg ellipticine per kg body weight as described 
previously (Stiborová et al., 2008). Ellipticine was adminis‑
tered as 10 mg/ml solution in distilled 1% acetic acid, control 
animals (n = 3) received solvent only.
To  evaluate  the  BaP‑mediated  induction  of  CYP1A, 
groups (n = 3) of HRN™ and WT female mice were treated 
with 125 mg BaP per kg body weight once daily for five days 
by intraperitoneal injection. BaP was dissolved in corn‑oil 
at a concentration of 12.5 mg/ml, control animals (n = 3) 
received solvent only (Arlt et al., 2008).
Preparation of microsomes and assays
Microsomes were isolated from pooled rodent livers as 
described (Stiborová et al., 2003b). Protein concentrations 
in the microsomal fractions (bicinchoninic acid protein 
assay with bovine serum albumin as a standard), the activi‑
ties of hepatic microsomal CYP1A1/2 (7‑ethoxyresorufin 
O‑deethylation, EROD) and POR (using cytochrome c) as 
well as the protein levels of these enzymes (Western Blot) 
were determined as described previously (Stiborová et al., 
2003a,b, 2005).
Oxidation  of  ellipticine  by  hepatic  microsomes. 
Incubation mixtures contained 50 mM potassium phosphate 
Figure 2. Metabolic activation and DNA adduct formation by benzo(a)pyrene: The typical 3-step activation process with contribution of CYP1A1 
or CYP1B1 and epoxide hydrolase leads to the formation of the ultimately reactive species, benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide (BPDE) 
that can react with DNA, forming adducts preferentially at guanine residues.163
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buffer (pH 7.4), NADPH‑generating system (1 mM NADP+, 
10 mM D‑glucose 6‑phosphate, 1 U/ml D‑glucose 6‑phos‑
phate dehydrogenase), 0.2 mg microsomal protein, 10 μM 
ellipticine (dissolved in 5 µl methanol) in a final volume of 
500 μl. The reaction was initiated by adding the substrate. 
After incubation in open glass tubes (37°C, 20 min) the 
reaction was stopped by adding 100 μl of 2 M NaOH, 5 μl 
of 1 mM phenacetine in methanol was added as an internal 
standard. Ellipticine metabolites were extracted twice with 
ethyl acetate (2 × 1 ml) and analyzed by HPLC as described 
(Stiborová et al., 2006; 200ß). 
Activation of ellipticine or BaP by hepatic microsomes
Incubation mixtures (final volume of 750 μl) used to asses 
DNA adduct formation consisted of 50 mM potassium phos‑
phate buffer (pH 7.4), 1 mM NADPH, 0.5 mg of microsomal 
proteins and 0.5 mg of calf thymus DNA. Incubations were 
also carried out in the presence of a COX cofactor, 0.1 mM 
arachidonic acid instead of NADPH, and additionally 5 mM 
magnesium chloride. The reaction was initiated by adding 
0.1 mM ellipticine (dissolved in 7.5 μl methanol) or 0.1 mM 
BaP (dissolved in 7.5 μl dimethyl sulphoxide). Incubations 
at 37°C were carried out for 30 or 90 min with ellipticine 
or BaP, respectivelly. DNA was isolated from the residual 
water phase by the phenol/chloroform extraction method as 
described (Stiborová et al., 2001). 
Inhibition studies
The following chemicals were used to inhibit the activa‑
tion of ellipticine and BaP by mouse hepatic microsomes: 
α‑naphthoflavone (α‑NF), which inhibits CYP1A1 and 1A2; 
indomethacin, a selective inhibitor of COX; α‑lipoic acid 
(α‑LA), which inhibits POR; ellipticine, frequently utilized 
as competitive inhibitor of CYP1A1 enzyme. Inhibitors were 
added to incubation mixture in 7.5 µl of methanol to yield 
final concentrations of 0.1 mM and pre‑incubated at 37 °C 
for 10 min with NADPH prior to adding substrate (ellipticine 
or BaP) and then incubated for as described above. After the 
incubation, DNA was isolated as described above.
Measurement of DNA adducts
32P‑postlabeling  analysis  with  nuclease  P1  enrichment, 
thin‑layer chromatography (TLC) and high performance 
liquid chromatography (HPLC) of 32P‑labelled 3’5’‑deoxy‑
ribonucleoside bisphosphate adducts with ellipticine were 
done as reported recently (Stiborová et al., 2001; 2003a; 
2004; 2007a). DNA adducts formed by BaP were analyzed 
 
Figure 3. Induction of CYP1A1 (A,C) and 1A2 (b,D) proteins in livers of male (A,b) and female (C,D) rats, uninduced or treated with 4, 40 or 80 mg 
of ellipticine per kg of body weight. Inset in A and C: immunoblots of microsomal CYP1A1 and 1A2 from untreated and ellipticine-treated male 
and female rats, respectively, stained with antibody against rat CYP1A1. Mean values shown in figure represent results obtained from livers of 
three rats (n=3), SD < 15%. Values significantly different from the control: *p<0.05, **p<0.01, ***p<0.001.164
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analogously,  using  the  32P‑postlabeling  technique  as 
described previously (Arlt et al., 2008).
Results
Induction of hepatic CYP1A by ellipticine and BaP
Ellipticine and BaP induced expression of CYP1A1 and 1A2 
proteins, which leads to an increase their enzymatic activi‑
ties in livers of animal models used in the experiments (rats 
for ellipticine and mice for BaP) (Figures 3 and 4). 
As  shown  in  Figure  3,  the  induction  of  CYP1A  by 
ellipticine was dose‑dependent. The increase in expression 
of CYP1A proteins correlated with that in specific CYP1A‑
mediated activity, EROD (Table 1). 
In the case of BaP, mouse models, HRN™ and its parental 
WT‑line, were utilized for the induction experiments. HRN™ 
mice were found to be more susceptible to BaP‑mediated 
CYP1A induction than the WT mouse line (Figure 4A). 
Using this model, lacking hepatic POR, we also evaluated 
whether expression of this enzyme is influenced by treat‑
ing animals with BaP. Treatment of mice with BaP led to 
a moderate increase in expression of hepatic POR in both 
WT (1.2‑fold increase) and HRN™ mice (1.4‑fold increase). 
In spite of POR deficiency, CYP1A activity (EROD) was 
restored by BaP treatment in HRN™ mice, representing the 
73‑fold increase in EROD activity in microsomes of unin‑
duced WT mice and 30 % of this activity in BaP‑induced 
WT mice (Figure 4B). 
DNA adduct formation in vivo
In further part of the study, we evaluated the potential of 
ellipticine and BaP to induce DNA adduct formation in vivo. 
Mice were used as models in these experiments. Treatment 
of individual mouse strains with ellipticine and BaP resulted 
in DNA adduct formation (Figure 5–7). The livers of all 
animal models were the major target organ for DNA adduct 
formation. Comparative analyses on TLC and HPLC have 
shown that DNA adduct formation in vivo proceeds via 
the reactive metabolite BPDE bound to the N2 position of 
guanine (dG‑N2‑BPDE) for BaP (Figures 2 and 6) and via 
13‑hydroxy‑ and 12‑hydroxyellipticine in the case of the 
two major ellipticine‑derived DNA adducts (spots 1 and 2 
in Figures 1 and 5). 
The experiments employing the mouse models helped us 
to improve our knowledge on the efficiency of CYPs to acti‑
vate ellipticine and BaP. Levels of ellipticine‑derived adducts 
in livers of HRN™ mice (Figure 5E) were reduced (by up to 
 
Figure 4. Induction of CYP1A (A,b) and POR (C,D) protein levels (A,C) and activities (b,D) in livers of female mice with deleted (HRN™) or intact (WT) 
liver POR, uninduced or treated (i.p.) with 5 × 125 mg of BaP per kg of body weight. Inset in A: immunoblots of microsomal CYP1A1/2 stained with 
chicken antibody against rat CYP1A1. Inset in C: immunoblots of microsomal POR stained with chicken antibody against rabbit POR. Microsomes 
were pooled from livers of 3 animals. Mean and SD evaluated from three separate experiments (n=3). ND = not detectable at used conditions.165
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65%) relative to levels in WT mice (Figure 5D), indicating 
that POR‑mediated CYP enzyme activity is important for 
the oxidative activation of ellipticine to metabolites generat‑
ing these adducts. 
In contrast to these results, the highest DNA binding of 
BaP was observed in livers of HRN™ mice (Figure 6A) which 
was 6.4‑fold (p<0.01) higher than DNA binding in WT mice 
(Figure 6B). This unexpectable finding indicates increasing 
the CYP‑mediated activation of BaP by lack of POR in the 
liver.
Activation of ellipticine and BaP by hepatic microsomes 
In order to further investigate the participation of CYPs in 
activation of ellipticine and BaP and which of these enzymes 
play the major role, the in vitro experiments were carried out. 
First, incubations of DNA with BaP and/or ellipticine with 
microsomes isolated from livers of HRN™ and WT mice, 
untreated or treated with BaP, were performed. In all cases, 
the patterns of DNA adducts formed by ellipticine and BaP in 
these experiments were essentially the same as those found 
in vivo (Figures 5 and 6), generated by the pathways shown in 
Figures 1 and 2. The identity of adducts formed by both com‑
pounds in vitro with those formed in vivo was proved using 
the TLC and HPLC‑cochromatography (data not shown).
Hepatic  microsomes  isolated  from  animals  treated 
with ellipticine or BaP were always more effective to form 
ellipticine‑ and BaP‑derived DNA adducts (Figures 5 and 
7) than microsomes from untreated animals. A decrease in 
levels of ellipticine‑derived adducts formed by microsomes 
from HRN™ mice compared with WT‑mice (Figure 7C–D) 
correlated with almost 2‑fold lower levels of 13‑hydroxy‑ 
and 12‑hydroxyellipticine, the metabolites generating the 
ellipticine‑DNA  adducts,  formed  by  these  microsomes 
(Stiborová et al., 2008).
NADPH‑dependent activation of BaP was even 4‑ to 
7‑fold lower in HRN™ compared to WT mouse microsomes 
(Figure 7A–B). The study investigating the pattern of BaP 
metabolites formed by microsomes from livers of all mouse 
groups (control HRN™ and WT‑mice as well as these mice 
treated with BaP), which might explain this feature is under 
way in our laboratory. Preliminary results suggest that the 
treatment of WT mice with BaP influenced only the rela‑
tive metabolites ratio instead of the total efficiency of BaP 
metabolite formation.
In all model systems, the use of POR‑inhibitor (α‑lipoic 
acid), CYP1A‑inhibitors (α‑naphthoflavone, ellipticine) and a 
CYP3A‑inhibitor (ketoconazole) decreased the DNA‑adduct 
formation by both compounds (Figure 7). These results sug‑
gest that even very low levels of the POR enzyme in livers 
of HRN™ mice are still sufficient to mediate CYP‑catalyzed 
activation reactions.
In order to determine which CYPs and/or other enzymes 
are responsible for DNA adduct formation by both com‑
pounds,  modulation  of  microsome‑mediated  activation 
with cofactors and inhibitors of individual enzymes was 
utilized.  Addition  of  NADH,  a  cofactor  of  microsomal 
NADH:cytochrome b5 reductase, acting as second electron 
donor  for  CYP‑dependent  systems,  lowered  the  differ‑
ence between HRN™ and WT microsomal BaP‑activation 
(Figure 7A–B). Arachidonic acid (AA), a cofactor of COX‑
dependent oxidation, was effective to activate ellipticine 
to species forming DNA adducts (Figure 7C–D), but not 
to mediate the BaP‑DNA adduct formation (Figure 7A–B). 
On the contrary, an inhibitor of COX, indomethacin (IM) 
decreases  BaP  activation  in  incubations  with  hepatic 
microsomes  from  BaP‑treated  HRN™  mice,  by  30–40% 
(Figure7B). These results may indicate the participation 
of COX in activation of both compounds, but with lower 
efficiency than CYPs. 
table 1. Specific CYP1A activity (EROD) in hepatic microsomes of con-
trol and ellipticine-treated rats.
CYP  
activity Control rats ellipticine-treated rats
Male Female Male Female
EROD 80.7 ± 2.0 225.8 ± 50.5 551.4 ± 92.2 1737.5 ± 161.3
a Each value (pmol of reaction product/min/nmol CYP) represents the 
mean ± standard deviation of data from two rats in two separate assays 
(n=4). 
 
Figure 5. Autoradiographic profile of ellipticine-derived DNA adducts: 
- in vivo in liver DNA of ellipticine-treated rats (A); HRN™ (D) and WT (e) mice. 
- in vitro in calf thymus DNA after ellipticine activation with hepatic microsomes of untreated (b) 
and ellipticine-treated (C) male rats and wild-type mice (F)
- in vitro in calf thymus DNA reacted directly with ellipticine metabolites 13-hydroxyellipticine (G) or 12-hydroxyellipticine (H) (without enzymatic 
activation). Analyses were performed by the nuclease P1 version of the 32P-postlabelling assay.166
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Figure 6. Autoradiographic profiles of BaP-derived DNA adducts in vivo in liver DNA of HRN™ (A) and WT (b) mice treated with 5 times 125 mg 
of BaP/kg body weight and in vitro in salmon testis DNA modified with BPDE (C) (without enzymatic activation). Analyses were performed by the 
nuclease P1 version of the 32P-postlabelling assay.
Figure 7. DNA adduct formation after activation of BaP (A,b) or ellipticine (C,D) with microsomes from livers of HRN™ and WT mice, untreated 
(A,C), or treated with 5 × 125 mg/kg BaP (b,D). Each value represents the mean of two separate analyses (n=2). F = fold increase, WT mice: 
HRN™ mice; ND = not detected. Control = microsomes + DNA without cofactor; AA = arachidonic acid; IM = indomethacin; E = ellipticine; 
α-NF = α-naphthoflavone; α-LA = α-lipoic acid. 
Discussion
As shown in several studies published previously, ellipticine 
and BaP are two xenobiotics that react with DNA forming 
covalent DNA adducts (for a summary, see Stiborová et al., 
2006b; Arlt et al., 2008). This genotoxic effect is mediated 
by their CYP‑mediated metabolism. Although the CYP 
enzymes activating ellipticine and BaP to species binding to 
DNA in vitro have already been identified (Baird et al., 2005; 
Stiborová et al., 2001; 2003a; 2004; 2006a; 2008; Kotrbová 
et al., 2006; Arlt et al., 2008), the knowledge on the real 
impact of these CYPs on the activation of these compounds 
in vivo is limited. Likewise, the effects of repeated exposure 
of organisms to these compounds on enzyme‑mediated 
activation process are scarce.167
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To evaluate the contribution and importance of hepatic 
CYP enzymes to the activation of ellipticine and BaP in vivo, 
we have used in our former and present studies the rats 
and especially the HRN™ mice, lacking POR and thus also 
POR‑mediated CYP enzyme activity in the liver (Henderson 
et al., 2003; 2006), as model organisms. The use of the HRN™ 
mouse model has already contributed to resolve the in vivo 
enzymatic activation of several environmental toxicants, 
including carcinogenic 3‑nitrobenzanthrone, activated by 
cytosolic nitroreductases rather than microsomal POR, and 
its reductive metabolite 3‑aminobenzanthrone (Svobodová 
et al., 2007), whose activation is CYP‑dependent (Arlt et al., 
2003, 2004, 2005, 2006). 
Ellipticine and BaP significantly induced expressions of 
CYP1A1 and 1A2 proteins as well as their enzymatic activ‑
ity such as EROD in rodent livers. The CYP1A induction 
resulted in a significant increase in levels of ellipticine‑ and 
BaP‑derived DNA adducts in vitro, in incubations of ellip‑
ticine or BaP with microsomes from rats treated with these 
compounds than in incubations with control microsomes. 
This is an important finding, because CYP1A enzymes are 
essential for ellipticine and BaP metabolism. Indeed, the 
importance of POR‑mediated CYP1A1 activation of both 
compounds in vitro was confirmed by inhibition studies 
using a specific POR inhibitor, α‑lipoic acid, and a CYP1A 
inhibitor, α‑naphtoflavone. 
Analogously to the results found in vitro, the levels of 
two major DNA adducts in animals treated with ellipticine 
were significantly decreased in liver DNA of HRN™ mice, 
confirming the importance of CYP enzymes in ellipticine 
activation in this organ in vivo. Inhibition of NADPH‑
dependent ellipticine activation in hepatic microsomes of 
HRN™ and WT mice by α‑NF and ketoconazole suggests 
that CYPs of 1A and 3A subfamilies play a major role in this 
process in mice livers, analogously to human and rat livers 
(Stiborová et al., 2001; 2003a, b). Nevertheless, the reduction 
of DNA adduct formation in the liver of HRN™ mice was 
not absolute, being ~65%. Likewise, the decrease in levels of 
these two ellipticine‑DNA adducts in hepatic microsomes 
of HRN™ mice caused by inhibitors of POR and CYPs was 
between 40–65%. These results suggest that other enzymes 
may also activate ellipticine in mice livers. A potential of 
arachidonic acid, a cofactor of COX enzymes, to increase 
the formation of these adducts in mice hepatic microsomes 
in vitro indicate that COX might be one of such enzymes. 
On the contrary, BaP‑induced DNA adduct formation in 
vivo was significantly increased in liver of HRN™ compared 
to WT mice, indicating that the real function of POR‑
mediated CYPs reactions is the BaP detoxification. Taken 
our results together with those from the CYP1‑deletion 
studies  (Uno  et  al.,  2004,  2006),  there  is  a  remarkable 
discrepancy between the in vivo DNA adduct levels and in 
vitro BaP activation, which is still very difficult to explain. 
Although hepatic CYP enzyme activity has been essentially 
inactivated by the conditional deletion of hepatic POR, 
in non‑parenchymal liver cells, the POR deletion may be 
incomplete. This residual POR activity, in combination with 
more pronounced induction of CYP enzymes (and probably 
also by induction of POR) in livers of HRN™ mice liver may 
explain these in vitro findings. Another explanation could 
be the induction of other metabolizing enzymes. 
Taken together, these results show evidence of the cru‑
cial role of CYP1A enzymes in ellipticine and BaP genotoxic 
effect in vivo. By inducing CYP1A1/2, both compounds 
modulate their either pharmacological (ellipticine) and/or 
genotoxic potential (both chemicals); ellipticine increases 
its own metabolism leading to enhanced formation of reac‑
tive species forming DNA adducts and BaP enhances its 
detoxification process. 
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